Brind.

Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.

2 reports, 2 independent Updated Oct 12
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.

Who's involved

What this event is mainly about
Biogen

How it developed

Newest first. Tap a step to see who reported it.
  1. JPMorgan upgraded Biogen stock following the Apellis acquisition.1 source
  2. Biogen stock outperformed S&P 500; financing needed for Apellis acquisition.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped